Welcome to our dedicated page for Avenue Therapeutics news (Ticker: ATXI), a resource for investors and traders seeking the latest updates and insights on Avenue Therapeutics stock.
Avenue Therapeutics (ATXI) generates news coverage centered on clinical development milestones, regulatory interactions, and corporate developments for its two primary programs: intravenous tramadol and BAER-101. As a clinical-stage specialty pharmaceutical company, Avenue's newsworthy events typically involve clinical trial progress, FDA communications, and strategic corporate actions.
The company's news flow reflects the nature of pharmaceutical development: regulatory milestone announcements, clinical trial enrollment updates, study completion notifications, and FDA correspondence summaries. For IV tramadol, coverage focuses on Phase 3 clinical development activities, regulatory pathway progress, and safety study designs addressing opioid-related concerns. BAER-101 developments include preclinical research presentations, mechanism of action studies, and potential therapeutic applications in neurological conditions.
Corporate news includes financial reporting through quarterly results, capital structure changes such as warrant exercises or reverse stock splits, participation in investor conferences, and strategic acquisitions or partnerships that expand the company's therapeutic pipeline. Publications in peer-reviewed journals represent important validation of research findings and contribute to the scientific understanding of the company's programs.
Following Avenue's news provides insight into how specialty pharmaceutical companies navigate regulatory pathways, manage clinical development timelines, and address safety questions for novel formulations in controlled substance categories. The news archive documents the progression of pain management alternatives through the FDA approval process and the development of neurological therapies targeting specific receptor systems.
Avenue Therapeutics (OTC: ATXI) announced that its majority-owned subsidiary Baergic Bio has been acquired by Axsome Therapeutics (NASDAQ: AXSM) for worldwide rights to BAER-101 (to be called AXS-17), an oral GABAA α2,3-selective PAM being evaluated for epilepsy.
Terms include a $0.3 million upfront payment, up to approximately $82 million in potential development, regulatory and sales milestones, plus a tiered mid-to-high single-digit royalty on global net sales; Avenue expects to receive ~74% of future payments and royalties.
Avenue Therapeutics (ATXI) reported Q3 2024 financial results and pipeline updates. The company expects topline data from its Phase 1b/2a trial of AJ201 for spinal and bulbar muscular atrophy around year-end 2024. The trial enrolled 25 patients to evaluate safety and tolerability. Cash position was $2.6M as of September 30, 2024. Q3 R&D expenses increased to $2.3M from $0.9M year-over-year, while G&A expenses decreased to $0.8M from $1.2M. Net loss was $(3.1)M or $(1.92) per share. The company also plans Phase 2a trials for BAER-101 in epilepsy and a Phase 3 safety study for IV tramadol, both pending additional financing.
Avenue Therapeutics, Inc. (Nasdaq: ATXI), a specialty pharmaceutical company focusing on neurologic disease treatments, has announced its participation in Maxim Group's 2024 Healthcare Virtual Summit. The company's CEO, Alexandra MacLean, M.D., will engage in a fireside chat on Tuesday, October 15, 2024, at 1:30 PM ET.
The event will be accessible to registered attendees, and investors can sign up or log in to the conference through a provided link. This participation highlights Avenue Therapeutics' commitment to engaging with the investment community and sharing insights about their developments in the neurologic disease treatment sector.
Avenue Therapeutics (Nasdaq: ATXI), a specialty pharmaceutical company focusing on neurologic disease treatments, has announced its participation in two upcoming investor conferences. Dr. Alexandra MacLean, the company's CEO, will represent Avenue at these events:
1. H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, in New York, featuring a company presentation and one-on-one meetings.
2. Lake Street Capital Markets BIG8 Conference on September 12, 2024, in New York, offering one-on-one meetings.
The H.C. Wainwright presentation will be available for on-demand viewing by conference attendees starting September 9, 2024, at 7:00 a.m. ET. These conferences provide Avenue Therapeutics with opportunities to showcase their progress and engage with potential investors.
Avenue Therapeutics (NASDAQ: ATXI) reported Q2 2024 financial results and corporate highlights. Key points:
- Last patient visit completed in Phase 1b/2a trial of AJ201 for spinal and bulbar muscular atrophy (SBMA); topline data expected in H2 2024
- Raised $4.4 million from warrant exercise in May 2024
- Cash position: $4.9 million as of June 30, 2024
- Q2 2024 net loss: $2.7 million ($6.43 per share)
- R&D expenses: $1.4 million, down from $3.0 million in Q2 2023
- G&A expenses: $1.5 million, up from $0.9 million in Q2 2023
Avenue continues to advance its pipeline for neurologic diseases, with AJ201 being the most advanced investigational treatment for SBMA in the U.S. The company also plans to initiate a Phase 2a trial of BAER-101 for epilepsy, subject to additional financing.
Avenue Therapeutics (Nasdaq: ATXI), a specialty pharmaceutical company, will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference. The company's CEO, Dr. Alexandra MacLean, will present at the event. The presentation will be accessible to registered attendees on-demand starting on Thursday, June 27, 2024, at 7:00 a.m. ET. Avenue Therapeutics focuses on developing and commercializing therapies for neurologic diseases.
Avenue Therapeutics announced the completion of the last patient visit in its Phase 1b/2a clinical trial of AJ201, aimed at treating spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's Disease.
The company anticipates reporting topline results by mid-2024. The 12-week, multicenter, randomized, double-blind trial included 25 patients, focusing on assessing the safety and tolerability of AJ201, with secondary endpoints examining pharmacokinetic and pharmacodynamic data.
CEO Alexandra MacLean expressed gratitude to all stakeholders involved and highlighted the drug's promising preclinical efficacy and safety profile. The trial is critical, as there are currently no approved treatments for SBMA.
Further study details are available on ClinicalTrials.gov under the identifier NCT05517603.
Avenue Therapeutics (Nasdaq: ATXI) reported its first-quarter 2024 financial results and recent corporate highlights. The company raised $9.4 million in gross proceeds from warrant exercises since January 2024 and increased its cash position to $3.2 million by March 31, 2024. Avenue has made significant progress with its lead clinical program AJ201 for spinal and bulbar muscular atrophy (SBMA) and presented promising preclinical data for BAER-101 in epilepsy treatment. The company plans to initiate a Phase 2a trial for BAER-101 pending necessary financing. Additionally, Avenue reached an agreement with the FDA on the Phase 3 study design for IV tramadol. Research and development expenses rose to $2.4 million, and general and administrative expenses increased to $1.3 million for the first quarter of 2024. Net loss narrowed to $4.3 million from $7.5 million in the same period last year.
Avenue Therapeutics, Inc. (Nasdaq: ATXI) announced the immediate exercise of outstanding warrants for $4.4 million in gross proceeds. The warrants were issued with varying exercise prices and will result in the purchase of 689,680 shares of common stock at a reduced price of $6.20 per share. The proceeds are expected to be used for general corporate purposes, and the transaction is set to close on or about May 1, 2024.
FAQ
What is the current stock price of Avenue Therapeutics (ATXI)?
What is the market cap of Avenue Therapeutics (ATXI)?
